ClinicalTrials.gg

Purpura, Thrombocytopenic, Idiopathic clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 505 studies for Purpura, Thrombocytopenic, Idiopathic across more than 10 countries. 160 are recruiting or about to start. 475 of them are mainly about Purpura, Thrombocytopenic, Idiopathic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-18.

ClinicalTrials.gov finds 559 studies for Purpura, Thrombocytopenic, Idiopathic. How that becomes 502 hereChecked on ClinicalTrials.gov . The studies here are updated every night.

This page counts the studies the registry files under Purpura, Thrombocytopenic, Idiopathic, and those it files under no condition that list Purpura, Thrombocytopenic, Idiopathicthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Only this comparison waits for its turn: it is asked again about once a week, so between two checks the registry's number can run a little ahead of it. How condition pages count

  1. 559Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −7List Purpura, Thrombocytopenic, Idiopathic as a condition, but the registry did not file them under itMost often written as “Chronic Immune Thrombocytopenia” (2), “Auto-immune Thrombocytopenic Purpura” (1), and “Lymphoma Idiopathic Thrombocytopenic Purpura” (1). The registry filed them under other conditions only, most often Anemia, Hemolytic, Autoimmune (4) and Purpura (2).
  3. −50Match it another way35 name it in the title, 2 in a keyword, and 13 by a synonym or other text the search reads.
  4. 502The count on this page20 of them list Purpura, Thrombocytopenic, Idiopathic in their own words; the registry filed them under no condition.

Status

Completed
200
Recruiting
104
Status unknown
81
Not yet recruiting
50
Terminated
26
Withdrawn
24

Phase

Phase 2
172
Phase 3
124
Phase 1
65
Phase 4
29
Early Phase 1
9

Where

China
187
United States
110
France
61
Spain
51
United Kingdom
50
Italy
47

Who develops what

Add Purpura, Thrombocytopenic, Idiopathic to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 37 programs from 34 companies, 31 with this as their studies’ main aim; 9 with a live phase 3 study; 13 primary completions in the next 12 months. Compare Novartis, Amgen and argenx here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
eltrombopagRecent, limited
Evidence
  • NCT05653219 · Novartis · Phase 3 · live · background · “Eltrombopag” · registered Nov 2022
  • NCT01433978 · Eisai Co., Ltd. · Phase 3 · comparator · “Eltrombopag” · registered Sep 2011
GlaxoSmithKline59% of its industry studiesUS: off-patent, 11 generics marketedEU: off-patent, 2 generics authorized11 study
PrednisoneRecent, limitedPhase 4 trial recorded
Evidence
  • NCT07700238 · Amgen · Phase 3 · live · background · “Predniso(lo)ne” · registered Jul 2026
Johnson & Johnson11% of its industry studies11 study
Adrenal Cortex HormonesRecent, limited
Evidence
  • NCT05653349 · Novartis · Phase 3 · live · background · “Corticosteroids” · registered Nov 2022
—11 study

3 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
rilzabrutinibApproved: US 2025 · EU 2025☆ Track2 live phase-3 studies: NCT07007962, NCT07216079Sanofi
Immunoglobulins, IntravenousApproved: EU 2006☆ Track1 live phase-3 study: NCT07059000kedrion s p a
Human immunoglobulin (pH4) for intravenous injection☆ Track1 live phase-3 study: NCT07233213Grand Shuyang Life Sciences (Chengdu) Co., Ltd.
TQB3473☆ Track1 live phase-3 study: NCT06900920Sino Biopharmaceutical Limited
efgartigimod alfaApproved: US 2021 · EU 2022☆ Track3 live phase-3 studies: NCT07194850, NCT04812925, NCT06544499argenx

The 5 in phase 3 with the nearest primary completion, of 37 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (13)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 25 Nov 2026 est.rilzabrutinib · Sanofi · Phase 3 main aimNCT07216079 Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan — primary endpoint: AEs including SAEs and AESIs · 3 enrolled
  • Dec 2026 est.Immunoglobulins, Intravenous · kedrion s p a · Phase 3 main aimNCT07059000 A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP) — primary endpoint: Rate of subjects with response (R) · 40 enrolled
  • Dec 2026 est.Human immunoglobulin (pH4) for intravenous injection · Grand Shuyang Life Sciences (Chengdu) Co., Ltd. · Phase 3 main aimNCT07233213 An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia — primary endpoint: Improved platelet response within 7 days of the first transfusion · 36 enrolled

10 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Purpura, Thrombocytopenic, Idiopathic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 13 open · JAK inhibitors 4 open · Corticosteroids 3 open · Proteasome inhibitors 1 open · Calcineurin inhibitors 1 open

Coming up

50studies finish main data collection within a year9 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger. 27 (26%) take children under 18. 1 (1%) are for women only and 0 (0%) for men only; 4 (4%) take healthy volunteers.

Recruiting studies that take each age, of 104
AgeWomenMen
1019 (18%)19 (18%)
1894 (90%)93 (89%)
3090 (87%)89 (86%)
4090 (87%)89 (86%)
5090 (87%)89 (86%)
6585 (82%)85 (82%)
7572 (69%)72 (69%)
8554 (52%)54 (52%)

Across all 505 studies, recruiting or not: 41% stop at 75 or younger and 24% at 65; 25% take children; 2% are for women only and <1% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Purpura, Thrombocytopenic, Idiopathic studies take

Of 66 phase 2 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 34 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 126 mo11–42 · 27 studies——
Phase 234 mo17–41 · 66 studies——
Phase 328 mo22–49 · 58 studies25 mo21–44 · 42 studies—
Observational55 mo35–… · 31 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 20, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 505. Browse all 505 → or search them.